Pharma-Bio Serv, Inc. Reports Earnings Results for the Full Year Ended October 31, 2023
January 29, 2024 at 04:57 pm EST
Share
Pharma-Bio Serv, Inc. reported earnings results for the full year ended October 31, 2023. For the full year, the company reported sales was USD 16.98 million compared to USD 19.4 million a year ago. Net income was USD 1.31 million compared to USD 1.01 million a year ago.
Basic earnings per share from continuing operations was USD 0.057 compared to USD 0.044 a year ago. Diluted earnings per share from continuing operations was USD 0.057 compared to USD 0.044 a year ago.
Pharma-Bio Serv, Inc. is a compliance and technology transfer services consulting company. The Company operates through four segments: Puerto Rico technical compliance consulting, United States technical compliance consulting, Europe technical compliance consulting, and Puerto Rico microbiological and chemical laboratory testing division (Lab). The Company provides a range of compliance-related consulting services. The Company provides microbiological testing services and chemical testing services through its laboratory testing facility in Puerto Rico. The Company's technical consulting services include regulatory compliance, validation, technology transfer, engineering, project management and process support. The Company markets its services to pharmaceutical, chemical, biotechnology, medical devices, cosmetic and food industries, and allied products companies in Puerto Rico, the United States, Europe and Brazil.
PHARMA-BIO SERV, INC. 
